The stock of the biotech company based in Lunel closed the session on Thursday, October 16, at €33.68, up 2.62% from the previous day's close of €32.82. This increase, which exceeded that of the CAC 40 at 1.38% on the same day, is part of a marked bullish trend: over the last seven days, the stock has jumped 20.11%, bringing its three-month performance to 107.4% and its annual increase to 110.2%. The traded volumes accounted for 0.44% of the capital, a moderate level indicating some stabilization after the strong fluctuations of previous sessions.
Recent Developments
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
This movement follows the approval on October 10 by the U.S. Food and Drug Administration of the extended indication of UZEDY for the treatment of type I bipolar disorder in adults. This announcement triggered a surge of 21.06% on Monday, October 13, bringing the price to €33.22. The following sessions were characterized by a consolidation phase, with a slight increase of 0.84% on October 14 and a decline of 2.03% on the 15th, before today's rebound. Following this approval, the TP ICAP Midcap research office raised its price target from €27 to €30, highlighting the commercial prospects of the product developed in partnership with Teva Laboratories.
Technical Analysis
Technically, the Relative Strength Index (RSI) reaches 87, a very high level that generally signals a short-term overheating situation. The stock is trading above its resistance threshold at €33.50, a zone that had previously acted as a ceiling, and touches the upper limit of the Bollinger Bands at €33.55, illustrating the strong buying pressure in recent days. The gap with the moving averages confirms the extent of the progress: the price is 60% above its 50-day average (€20.87) and more than double its 200-day average (€16.75). The MACD, which measures the momentum of price movements, remains positive, indicating persistent bullish momentum. With a beta of 0.09, MedinCell also shows a very low correlation with the CAC 40, its evolution being mainly driven by its own catalysts.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
